Eclipsebio Raises $14M in Series A Financing


Eclipsebio, a San Diego, CA-based RNA genomics company, raised $14M in Series A funding.

The round was led by Alexandria Venture Investments and iGlobe, with participation from Photon Venture Alpha and Phoenix Venture Partners.

The company intends to use the funds to expand its suite of RNA genomics technologies and products.

Led by CEO Peter Chu, Eclipsebio is a private biotechnology company building the RNA genomics team to develop technologies to enable effective development RNA therapeutics. The company offers its end-to-end RNA genomics products as services and kits and also provides custom RNA genomics services for select partners.

At the beginning of the year, Eclipsebio relocated into a new 18,000-square-foot corporate and research headquarters located in Sorrento Valley, San Diego. In this new location, the company will continue to expand its team of molecular biologists and bioinformatics scientists as well as its commercial group to support business growth through increased awareness, education, and client-facing functions.

Eclipsebio also announced the appointment to the company’s board of directors of Hallie Kuhn, Ph.D., vice president of science and technology at Alexandria Real Estate Equities, Inc. and Alexandria Venture Investments. Dr. Kuhn joins Daniel Vasella, M.D., former CEO and chairman of Novartis, and the company’s cofounders as board members.